CTRI/2021/03/032280尚未招募3 期
CHAL0!2.0 for increasing HIV testing and care engagement for MSM on the internet
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •(1) >=18
- •years old; (2) live or work in Mumbai; (3) fluent in Hindi or English, (4) identify as male, (5) anal sex
- •with men in past 2 years; (6) report that they have either never tested for HIV, are unaware of HIV test
- •results, or are HIV-negative with last HIV test >6 months ago and anal sex since last test; (7) able to
- •provide and verify Whatsapp mobile number and email address; (8) willing to answer online surveys
- •for 18 months; (9) have not used services through HST in past 12 months (verified by checking
- •mobile phone number against HSTâ??s client registry); and (10) have not participated in a prior HIV
- •research study (by self-report).
排除标准
- 未提供
研究者
相似试验
已完成
2 期
BYLIEVE: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatmentsbreast CancerNL-OMON52978ovartis6
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1 monoclonal antibody) in patients with rheumatoid arthritis - NDMedDRA version: 6.1Level: PTClassification code 10039073rheumatoid arthritisEUCTR2007-001665-15-ITOVARTIS FARMA179
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisMedDRA version: 8.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisRheumatoid ArthritisEUCTR2007-001665-15-BEovartis Pharma Services AG179
进行中（未招募）
不适用
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisRheumatoid ArthritisEUCTR2007-001665-15-DEovartis Pharma Services AG179
撤回
2 期
A 54-week, phase II, multi-center, open-label extension study to evaluate the efficacy, safety and tolerability of ACZ885 (anti-interleukin-1beta monoclonal antibody) in patients with rheumatoid arthritisNL-OMON31801ovartis18